You have successfully logged out.



BASKET-SMALL 2 (3-year data available – October 2020)

Basel Stent Kosten Effektivitäts Trial Drug Coated Balloons vs. Drug Eluting Stents in Small Vessel Interventions

Jeger R et al. The Lancet, August 2018.

Trial Registration Number: NCT01574534 on

Jeger R et al. The Lancet, October 2020. Same trial registration.

Key findings

Largest randomized clinical trial with primary clinical endpoint, testing the efficacy of SeQuent® Please NEO (DCB) vs. 2nd generation DES for the treatment of small vessel coronary artery disease.

DCB-only treatment with SeQuent® Please NEO achieves clinical results comparable to 2nd generation DES implantation in de novo lesions up to 3 mm in reference vessel diameter.


Design: Investigator initiated | Randomized | Open-label | Prospective | Multicenter | Non-inferiority


Indication: Ischemic coronary artery disease (CAD) in native de novo lesions


Main inclusion criteria:

  • Vessel diameter ≥ 2 mm to < 3 mm
  • Native vessel
  • Successful pre-dilation according to consensus recommendations for DCB-usage


Primary outcome:

  • MACE @ 12 months (MACE includes: TVR, non-fatal MI, cardiac death)
  • MACE @ 36 months (MACE includes: TVR, non-fatal MI, cardiac death)


Secondary outcomes:

  • TVR, non-fatal MI, cardiac death, stent thrombosis, bleeding


Dual Antiplatelet Therapy (DAPT):

  • 4 weeks of DAPT in stable patients treated with DCB or 6 months for DES. In patients with acute coronary syndrome (ACS) 12-month DAPT


758 patients randomized after pre-dilation (86 % of 883 initially assessed patients)

  • 382 assigned for DCB-treatment, 376 for DES-treatment
  • Well-balanced demographic and procedural parameters between the treatment groups


Primary outcome: No statistical difference between groups

  • MACE @ 12 months 7.3% in the DCB group vs. 7.5% in the DES group (p=0.92)
  • The primary endpoint was met for non-inferiority at both time points (DCB not worse than DES)


Secondary outcome:

  • MACE @ 36 months 15% in both groups (p=0.95)
  • @ 12 months DCB vs. DES – cardiac death: 3.1 vs. 1.3 %, MI 1.6 vs. 3.5 % or TVR 3.4 vs. 4.5%
  • @ 36 months DCB vs. DES – cardiac death: 5 vs. 4 %, MI 6 vs. 6 % or TVR 9 vs. 9%


Other endpoints:

  • @ 12 months: Probable or definite thrombosis were low and comparable between DCB and DES patients (0.79 vs. 1.60 %). Rates of major bleeding were low and similar in DCB and DES patients (1.1 vs. 2.4 %).
  • @ 36 months: Probable or definite thrombosis (1% in DCB and 2% in DES, p=0.18). Rates of major bleeding (2% in DCB vs. 4% in DES, p=0.088) were numerically lower in the DCB group without statistical significance.


BASKET SMALL 2 is the largest randomized trial with primary clinical endpoint comparing DCB with 2nd generation DES in small vessel coronary artery disease – DCB is non-inferior to 2nd generation DES in the treatment of SVD.

Study flowchart

12-month follow-up:

n = 362
n = 376
TVR3.4 %4.5 %0.44
MI1.6 %3.5 %0.11
Cardiac death3.1 %1.3 %0.11
MACE7.3 %7.5 %0.92

36-month follow-up:

person_outline My B. Braun